'Magic number' 695 opens up new areas for Alzheimer's research

November 15, 2010

Alzheimer's disease is widely believed to be caused by the gradual accumulation in the brain of amyloid-beta peptide which is toxic to nerve cells. Amyloid beta peptide is formed from a protein known as APP, which is found in three forms. Most research into APP – a key area of study for the disease – does not distinguish between the different forms of the protein.

The findings, published in the Journal of Biological Chemistry, show that amyloid beta peptide is actually created mainly by just one form of APP – known as APP695 for the number of its amino acids. APP695 is found at greater concentration in brain and , but this study – funded by the Medical Research Council and the Alzheimer's Research Trust – is the first time the significance of that has been shown. This discovery will now enable research to focus more clearly on the exact mechanism by which amyloid beta peptide accumulates in the brain.

"Research into amyloid beta peptide has been going on for more than 20 years and while treatments have made it to clinical trials, nothing has proved truly effective against this disease," says Professor Tony Turner, from Leeds' Faculty of Biological Sciences, who co-led the research. "This could be because research to date has been a bit of a blunt instrument: scientists have essentially been working on too broad a field. Our findings will allow researchers to target their work much more precisely."

The study of APP695 also led the scientists to identify a potential new factor in the development of Alzheimer's. When APP is broken down, it forms another called AICD. The researchers discovered that AICD formed from APP695 switches on certain genes within nerve cells that may then damage the cell. The process is unique to nerve cells and AICD formed from the other forms of APP does not have this effect.

"AICD has been detected before, but because studies haven't differentiated between the different forms of APP, there was no consensus on its role," explains co-researcher Professor Nigel Hooper. "It seems likely that AICD formed from APP695 is a contributing factor in the deterioration in nerve and cells which leads to Alzheimer's. This provides another avenue for research into a potential cure for the disease."

Professor Chris Kennard, chair of the MRC Neurosciences and Mental Health Board, said: "This is the latest study from a long-term research collaboration to significantly further our understanding of neurodegenerative diseases, such as . It forms part of a £4.1m investment by the MRC and is a shining example of where fundamental research, which unravels the complex biology of disease, can provide the building blocks for potential treatments in future."

Dr Simon Ridley, Head of Research at the Alzheimer's Research Trust, said: "This study gives us important new insight into the role of APP in Alzheimer's disease, and could have significant implications for future research in this area. We must now build on these findings with more research, as this is the only way we will be able to find an effective treatment for dementia."

Over 820,000 people in the UK live with dementia and one in three over 65s will die with some form of the disease. The Alzheimer's Research Trust estimates that the annual cost to the UK economy is £23 billion.

Explore further: Scientists identify 'missing link' in process leading to Alzheimer's disease

Related Stories

Investigating the causes of Alzheimer's

November 22, 2007

Scientists at the University of Bristol are investigating what causes the leaks that develop in blood vessels in Alzheimer's disease, thanks to funding from the UK's leading dementia research charity, the Alzheimer's Research ...

Anti-inflammatory drug blocks brain plaques

June 24, 2008

Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells. Scientists had previously shown that ...

Epilepsy drug shows potential for Alzheimer's treatment

December 8, 2008

A drug commonly used to treat epilepsy could help clear the plaques in the brain associated with Alzheimer's disease, according to researchers at the University of Leeds. The plaques are known to lead to the progressive ...

New approach to Alzheimer's therapy

July 30, 2010

Researchers from the German Centre for Neurodegenerative Diseases and the Ludwig-Maximilians-Universitat in Munich have shown that the ADAM10 protein can inhibit the formation of beta-amyloid, which is responsible for Alzheimer's ...

Recommended for you

A new form of real gold, almost as light as air

November 25, 2015

Researchers at ETH Zurich have created a new type of foam made of real gold. It is the lightest form ever produced of the precious metal: a thousand times lighter than its conventional form and yet it is nearly impossible ...

New 'self-healing' gel makes electronics more flexible

November 25, 2015

Researchers in the Cockrell School of Engineering at The University of Texas at Austin have developed a first-of-its-kind self-healing gel that repairs and connects electronic circuits, creating opportunities to advance the ...

Getting under the skin of a medieval mystery

November 23, 2015

A simple PVC eraser has helped an international team of scientists led by bioarchaeologists at the University of York to resolve the mystery surrounding the tissue-thin parchment used by medieval scribes to produce the first ...

Atom-sized craters make a catalyst much more active

November 24, 2015

Bombarding and stretching an important industrial catalyst opens up tiny holes on its surface where atoms can attach and react, greatly increasing its activity as a promoter of chemical reactions, according to a study by ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.